If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
109.80    1.60 (1.48%)
Bid:
108.60
Ask:
109.20
Spread: 0.60 (0.552%)
Market Cap: £667.80m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Director Declaration

22 Jun 2022 17:21

RNS Number : 8659P
Syncona Limited
22 June 2022
 

Syncona Limited (the "Company")

Director Declaration

 

22 June 2022

In accordance with the requirements of the Listing Rule 9.6.14R, the Company advises the following change to directorships in other publicly quoted companies, held by the following member of the Board:

Virginia Holmes was appointed to Murray International Trust PLC on 22 June 2022.

Enquiries

Syncona Ltd

Andrew Cossar

Tel: +44 (0) 20 3981 7940

 

Citco Fund Services (Guernsey) Limited

Company Secretary

Tel: +44 (0) 1481 758200

 

About Syncona:

Syncona is a leading FTSE250 healthcare company whose purpose is to invest to extend and enhance human life by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Copies of this press release, a company results presentation, and other corporate information can be found on the company website at: www.synconaltd.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNQLLFLLQLLBBB
Date   Source Headline
18th Sep 20177:00 amPRNAutolus commences clinical trial programmes
15th Sep 20171:02 pmPRNUpdate on Nightstar proposed NASDAQ IPO
8th Sep 20174:39 pmPRNDirectorate Change
8th Sep 20172:40 pmPRNResult of AGM
1st Sep 20177:00 amPRNNightstar files registration for proposed IPO in the US
31st Aug 20179:58 amPRNTotal Voting Rights
29th Aug 201712:17 pmPRNMonthly Factsheet - July 2017
29th Aug 201712:15 pmPRNNet Asset Value(s)
25th Aug 20172:58 pmPRNDirectors Dealings
15th Aug 201711:46 amPRNIssue of Shares Pursuant to the 2017 Dividend
8th Aug 201712:02 pmPRNDirector/PDMR Shareholding
4th Aug 20175:32 pmPRNDirector/PDMR Shareholding
31st Jul 20174:39 pmPRN2017 Dividend Scrip Reference Price
31st Jul 20173:59 pmPRNNet Asset Value(s)
31st Jul 20173:58 pmPRNMonthly Factsheet - June 2017
31st Jul 20172:31 pmPRNDirector/PDMR Shareholding
26th Jul 20176:27 pmPRNDirector/PDMR Shareholding
21st Jul 201710:13 amPRNPublication of 2017 Annual Report & Notice of AGM
6th Jul 20177:00 amPRNPreliminary Results for the year ended 31 March 2017
30th Jun 20179:38 amPRNMonthly Factsheet - May 2017
30th Jun 20179:36 amPRNNet Asset Value(s)
28th Jun 20177:00 amPRNNightstaRx completes US$45m Series C investment round
31st May 201710:51 amPRNMonthly Factsheet - April 2017
31st May 201710:43 amPRNNet Asset Value(s)
23rd May 20177:00 amPRNBlue Earth Diagnostics achieves EMA approval on Axumin
28th Apr 20171:42 pmPRNMonthly Factsheet - March 2017
28th Apr 20171:37 pmPRNNet Asset Value(s)
28th Mar 20173:19 pmPRNMonthly Factsheet - February 2017
28th Mar 20173:18 pmPRNNet Asset Value(s)
24th Mar 20171:58 pmPRNNon-Mainstream Pooled Investments
24th Mar 20177:00 amPRNBlue Earth Diagnostics receives positive CHMP opinion
6th Mar 20177:00 amPRNCapital Markets Day
28th Feb 20179:24 amPRNMonthly Factsheet - January 2017
28th Feb 20179:20 amPRNNet Asset Value(s)
6th Feb 20175:23 pmPRNHolding(s) in Company
27th Jan 201712:40 pmPRNMonthly Factsheet - December 2016
27th Jan 201712:37 pmPRNNet Asset Value(s)
23rd Jan 20174:42 pmPRNNon-Mainstream Pooled Investments
30th Dec 201611:33 amPRNTotal Voting Rights
30th Dec 20169:47 amPRNMonthly Factsheet - November 2016
30th Dec 20169:45 amPRNNet Asset Value(s)
29th Dec 20164:19 pmPRNHolding(s) in Company
28th Dec 20164:57 pmPRNHolding(s) in Company
28th Dec 20167:00 amPRNHolding(s) in Company
23rd Dec 201611:37 amPRNHolding(s) in Company
22nd Dec 20164:54 pmPRNDirectors' dealing
21st Dec 20167:00 amPRNHolding(s) in Company
21st Dec 20167:00 amPRNHolding(s) in Company
21st Dec 20167:00 amPRNHolding(s) in Company
19th Dec 201610:00 amPRNChange of Name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.